Ascletis Pharma Inc. (HKEX: 1672) reported on July 27, 2026, that ASC37, its investigational GLP-1 receptor, GIP receptor and glucagon receptor triple peptide agonist, produced greater body-weight reduction than tirzepatide in an 11-day diet-induced obese mouse experiment. At an equal dose of 1 nanomole per kilogram administered subcutaneously once daily, mice receiving ASC37 lost 14.1% of their baseline body weight, compared with 7.5% for tirzepatide, representing an 88% relative difference that the company reported as statistically significant.
Higher ASC37 doses were associated with progressively larger reductions, reaching 30.1% at 10 nanomoles per kilogram and 41.5% at 30 nanomoles per kilogram. Those numbers make the study an attention-grabbing preclinical result, but they do not establish that ASC37 will produce comparable weight loss, tolerability or dosing convenience in people. The experiment was conducted in mice, lasted only 11 days and used daily administration rather than the once-monthly clinical regimen Ascletis ultimately wants to develop.
The announcement nevertheless advances the commercial narrative surrounding ASC37. Ascletis now plans to submit United States Investigational New Drug applications for both a once-monthly subcutaneous formulation and an oral formulation during the third quarter of 2026. The company previously expected an IND submission for the injectable candidate during the second quarter, meaning the latest disclosure represents a one-quarter shift from its January guidance.
The strategic challenge is formidable. ASC37 is still preclinical, while Eli Lilly and Company’s competing triple agonist retatrutide has produced positive results across multiple pivotal Phase 3 trials and is being prepared for a United States Biologics License Application submission in the first quarter of 2027. Ascletis is therefore not attempting to win a simple race to market. It must instead demonstrate that less frequent dosing, oral delivery or some other clinically relevant feature can compensate for entering human development substantially later.
What do the ASC37 mouse results actually demonstrate, and what remains unknown?
The most relevant comparison in the Ascletis experiment is the equal-dose analysis. Both ASC37 and tirzepatide were administered at 1 nanomole per kilogram once daily, with ASC37 producing a 14.1% body-weight reduction and tirzepatide producing a 7.5% reduction. The reported p-value of 0.0279 suggests that the difference was unlikely to have occurred by chance within the conditions of that experiment.
The study also produced a clear dose-response pattern. Weight reduction increased as the ASC37 dose rose from 1 to 10 and then 30 nanomoles per kilogram. Dose responsiveness is an important pharmacological signal because it supports the argument that the observed effect was associated with drug exposure rather than random variation.
However, the company’s release did not disclose the number of animals in each group, baseline weight distribution, food intake, drug exposure measurements, body-composition changes or whether the reduction came predominantly from fat mass, lean tissue, fluid or a combination of these factors. It also did not provide detailed tolerability findings or explain whether any animals discontinued treatment.
Those omissions do not invalidate the experiment, but they limit how confidently external readers can interpret its magnitude. A 41.5% reduction in body weight over 11 days is unusually large, making information on nutritional intake, hydration, activity, metabolic parameters and tissue composition particularly important.
The study also did not compare ASC37 directly with retatrutide, the triple agonist that most closely resembles ASC37’s intended mechanism. Tirzepatide activates GLP-1 and GIP receptors, while ASC37 and retatrutide additionally activate the glucagon receptor. The experiment consequently compares a triple agonist with a dual agonist, rather than establishing whether ASC37 is more effective than another triple agonist.
Most importantly, the mouse study does not show that ASC37 will work when administered once monthly. The animals received ASC37 once daily during the efficacy experiment. Ascletis separately reported that its Self Assembly Lipid Depot formulation produced an average observed half-life of approximately 17 days in non-human primates, compared with about 2.5 days for the retatrutide formulation used in that pharmacokinetic study. The pharmacokinetic observation supports further testing of monthly administration, but it is not the same as demonstrating sustained monthly efficacy in humans.
Why is Ascletis pursuing monthly dosing when retatrutide is already nearing submission?
Frequency of administration could become a meaningful point of differentiation in the obesity market, particularly as treatment increasingly moves toward long-term weight maintenance rather than short courses of rapid weight reduction.
Tirzepatide, semaglutide and retatrutide are designed for weekly administration. A genuinely effective once-monthly therapy could reduce the number of injections from approximately 52 to 12 per year. That may improve convenience for some patients and simplify distribution, storage and prescribing workflows, although adherence benefits would need to be demonstrated rather than assumed.
Monthly administration also creates new clinical risks. A formulation designed to release an active peptide over several weeks cannot be quickly removed if a patient develops intolerable adverse effects. Dose escalation may become more complicated, and clinicians may need to wait longer before determining whether a particular exposure level is appropriate.
This matters because gastrointestinal adverse effects and treatment discontinuations remain important considerations for incretin-based therapies. In Eli Lilly’s TRIUMPH-1 Phase 3 study, retatrutide produced average weight reductions of 19.0%, 25.9% and 28.3% at 80 weeks across its three studied doses. Nausea, diarrhoea, constipation and vomiting were among the most frequently reported adverse events, while discontinuation due to adverse events increased to 11.3% in the highest-dose group.
Retatrutide subsequently generated positive results in adults with obesity and type 2 diabetes and in people with severe obesity and established cardiovascular disease. Weight reduction reached 20.8% in TRIUMPH-2 and 22.6% in TRIUMPH-3 at 80 weeks, although detailed peer-reviewed reports for those studies remain pending.
ASC37 will ultimately be measured against this increasingly mature evidence package, not merely against tirzepatide-treated mice. Its monthly formulation must produce sustained exposure without excessive peak concentrations, accumulation, unpredictable release or tolerability problems. Human pharmacokinetic data will therefore be at least as important as the first weight-loss observations.
Could oral ASC37 offer a more valuable differentiation than the monthly injection?
Ascletis is developing ASC37 in both injectable and oral forms, creating two distinct commercial possibilities from the same peptide sequence. The oral candidate uses the company’s Peptide Oral Transport ENhancement Technology, known as POTENT, to increase peptide absorption through the gastrointestinal tract.
In a previous non-human primate study, Ascletis reported average absolute oral bioavailability of 4.2% for ASC37 tablets. The company said this was higher than the exposure achieved by oral formulations of several comparator peptides in its experiments, while the observed half-life of approximately 56 hours supported daily or potentially less frequent oral dosing. These remain company-reported animal data, and human absorption could differ materially.
An oral triple agonist could potentially address patients who prefer tablets to injections, but oral peptide development involves substantial formulation and manufacturing challenges. Peptides can be degraded in the digestive system, and relatively low or variable absorption may require larger quantities of active ingredient than an injectable product.
That can affect manufacturing capacity, cost of goods and dose-to-dose consistency. The commercial value of oral ASC37 will therefore depend not only on whether the tablet produces weight loss, but also on whether Ascletis can achieve predictable exposure across patients, food conditions and gastrointestinal environments.
Developing oral and injectable versions in parallel may broaden the eventual opportunity, but it also increases execution demands. Each formulation requires its own clinical pharmacology work, dose optimisation, stability programme, manufacturing controls and regulatory documentation. The proposed third-quarter IND submissions will clarify whether the United States Food and Drug Administration permits both versions to enter human testing on the anticipated timeline.
Why does ASC37’s 41-amino-acid structure matter to its regulatory strategy?
Ascletis engineered ASC37 with 41 alpha amino acids. Under the United States Food and Drug Administration’s regulatory definition, a protein is an alpha amino-acid polymer with a specific sequence that is greater than 40 amino acids in size. That threshold allows qualifying products to be regulated as biological products rather than conventional small-molecule drugs.
Ascletis consequently intends to pursue Biologics License Applications for the injectable and oral versions after successful completion of Phase 3 development. A BLA must contain extensive information covering manufacturing, chemistry, pharmacology, clinical pharmacology, safety and effectiveness before the product can be licensed for commercial marketing. Merely qualifying as a biological product does not reduce those evidentiary requirements.
Management has emphasised potential lifecycle advantages associated with biologic status, including a longer period before exposure to Medicare price negotiation than would generally apply to a small-molecule medicine. Ascletis has also highlighted the absence of a conventional pharmacy-compounding pathway for biologics.
The latter claim is supported by current United States Food and Drug Administration policy. Biological products are not eligible for the exemptions available to compounded drugs under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Federal law does not provide a pathway for marketing an externally prepared biologic outside the scope of an approved BLA, although the regulator has described limited circumstances involving mixing, diluting or repackaging.
That distinction could become commercially significant in the obesity market, where compounded semaglutide and tirzepatide products expanded during periods of shortage. The FDA has since tightened its position as supplies stabilised, reminding compounders that products considered essentially copies of commercially available medicines generally do not qualify for the relevant exemptions.
Biologic status does not, however, protect ASC37 from competition. An approved product could eventually face biosimilar development, newer branded medicines or alternative oral and injectable technologies. Regulatory classification may strengthen lifecycle management, but the fundamental commercial value will still depend on clinical performance, manufacturing reliability, payer acceptance and price.
How wide is the evidence gap between ASC37 and Eli Lilly’s retatrutide?
Retatrutide provides proof that simultaneous activation of GLP-1, GIP and glucagon receptors can produce substantial weight reduction in humans. A published Phase 2 trial reported an average reduction of 24.2% at 48 weeks with the highest studied retatrutide dose, supporting its progression into Phase 3.
The programme has since generated multiple positive pivotal readouts. In TRIUMPH-1, participants receiving the highest dose lost an average of 28.3% at 80 weeks, while a prespecified extension involving eligible participants with a baseline body mass index of at least 35 recorded an average 30.3% reduction at 104 weeks.
Retatrutide is also being studied across obesity-related conditions, including type 2 diabetes, obstructive sleep apnoea, knee osteoarthritis, cardiovascular disease, chronic back pain and metabolic liver disease. Eli Lilly plans a BLA submission in the first quarter of 2027 after completing its chemistry, manufacturing and controls package.
ASC37 has not yet been administered to a human participant. It has no human safety profile, no clinical dose, no validated titration schedule and no evidence demonstrating that its monthly depot can maintain therapeutic exposure for a complete dosing interval.
This does not make the programme commercially irrelevant. Later entrants can succeed when they provide a meaningful improvement in convenience, tolerability, effectiveness, manufacturing economics or patient segmentation. It does mean that describing ASC37 as superior to retatrutide, tirzepatide or another clinical therapy would be premature.
The first human study will need to determine whether the long exposure observed in non-human primates translates into people. Investigators will also need to examine whether glucagon-receptor activity contributes to desirable weight reduction without creating unacceptable effects on heart rate, glucose regulation, gastrointestinal tolerability or other metabolic parameters.
What must happen before ASC37 becomes a credible clinical and commercial asset?
The first measurable milestone is submission and acceptance of the planned IND applications. Ascletis must provide sufficient preclinical pharmacology, toxicology, manufacturing and formulation information for the FDA to allow human testing to proceed.
A Phase 1 programme would then be expected to examine safety, tolerability, pharmacokinetics and pharmacodynamics across ascending doses. For the monthly injection, the central question will be whether the depot releases ASC37 predictably for several weeks while avoiding excessive early exposure or prolonged adverse effects.
For the oral formulation, the study must establish whether adequate and consistent systemic exposure can be achieved in humans. Food effects, gastrointestinal variability and the amount of peptide required per tablet could materially influence the formulation’s practicality.
Human weight change may be observed during early trials, but Phase 1 studies are generally not designed to provide definitive efficacy conclusions. Dose selection, tolerability and exposure will determine whether ASC37 can progress into larger studies capable of testing meaningful weight-loss endpoints.
Ascletis must also manage an expanding metabolic pipeline that includes ASC30, ASC35, ASC36, ASC36_35, ASC39 and several fixed-dose combinations. The breadth provides multiple opportunities, but it may eventually force decisions about which programmes deserve the greatest clinical-development and manufacturing investment.
How should investors interpret the ASC37 announcement and Ascletis share sentiment?
The July 27 release was published at 6:10 a.m. Eastern Time, equivalent to 6:10 p.m. in Hong Kong. That was after the Hong Kong securities market’s closing auction, which ordinarily finishes between 4:08 p.m. and 4:10 p.m. Any market response specifically associated with the ASC37 data would therefore emerge in a subsequent trading session rather than the session preceding publication.
Recent Ascletis trading had already been volatile. Publicly indexed data showed the shares falling from HK$10.60 on July 16 to HK$8.37 on July 17 and closing at HK$8.44 on July 21. The indexed 52-week range at that point extended from HK$7.95 to HK$19.86. Those figures predate the ASC37 announcement and should not be presented as a reaction to it.
For investors, the mouse findings are best viewed as a pipeline-supporting signal rather than a clinical de-risking event. They strengthen the biological rationale for advancing ASC37, but they do not materially resolve the largest uncertainties surrounding human safety, monthly exposure, oral absorption or competitive effectiveness.
The next meaningful valuation steps are likely to be FDA acceptance of the INDs, initiation of human dosing, pharmacokinetic confirmation of monthly coverage and the first disclosed tolerability results. ASC37’s commercial proposition will become more credible only when the programme demonstrates that its long-acting design works in people rather than solely in animal models.
The programme therefore combines an unusually strong preclinical headline with an equally large translational burden. Ascletis has shown that ASC37 deserves clinical evaluation. The harder task begins when the company must prove that the same molecule can deliver predictable, tolerable and durable weight management across a full month in human participants.
